Physician profile
James E Mohyi
NPI 1255357992
$6,839.80
in general payments reported to CMS, 2019-2025
24 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $389 · 2021: $659 · 2022: $1,279 · 2023: $434 · 2024: $759 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,497.57 | 2019-2024 | Invega Trinza, Invega Sustenna, Xarelto |
| Astrazeneca Pharmaceuticals Lp | $840.22 | 2022-2025 | Wainua, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $697.70 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $529.78 | 2025 | Rezdiffra |
| Sanofi-Aventis U.S. LLC | $240.91 | 2019 | |
| Gilead Sciences, INC. | $222.68 | 2024 | Livdelzi, Epclusa |
| Romark Laboratories, Lc | $219.36 | 2019-2020 | |
| Biosense Webster, INC. | $145.83 | 2025 | Carto 3 |
| Terumo Medical Corporation | $125.00 | 2023 | Azur Cx Detachable |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.44 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $119.05 | 2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $113.91 | 2025 | Camzyos |
| Intercept Pharmaceuticals, INC. | $106.20 | 2020 | |
| Daiichi Sankyo INC. | $94.41 | 2022 | |
| Phathom Pharmaceuticals, INC. | $93.79 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92.89 | 2019-2023 | Repatha |
| Janssen Biotech, INC. | $90.87 | 2025 | Tremfya |
| Novo Nordisk INC | $89.09 | 2025 | Wegovy |
| Lantheus Medical Imaging, INC. | $87.63 | 2020-2022 | |
| Medtronic, INC. | $76.58 | 2021-2024 | Micra |
| Medtronic Vascular, INC. | $71.10 | 2019 | |
| Pfizer INC. | $66.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $53.40 | 2019 | |
| Edwards Lifesciences Corporation | $44.38 | 2024 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mohyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.